During Tuesday’s Current trade, Shares of HORSEHEAD HOLDING CORP. (NASDAQ:ZINC), lost -0.38% to $7.83.
Horsehead Holding Corp. (ZINC), the parent company of Horsehead Corporation, The International Metals Reclamation Company, LLC and Zochem, Inc. plans to release its 2015 second quarter earnings before the market opens on Friday, August 7, 2015.
Horsehead Holding Corp., together with its auxiliaries, produces and sells zinc and nickel-based products primarily in the United States and Canada. The company operates through three segments: Horsehead, Zochem, and INMETCO. The Horsehead segment processes electric arc furnace dust and other zinc-bearing material to produce and sell zinc and other metals.
Shares of Brixmor Property Group Inc (NYSE:BRX), inclined 0.88% to $23.99, during its current trading session.
Brixmor Property Group Inc. (BRX) declared its results of operations for the second quarter ended June 30, 2015.
Dividend
- The Company’s Board of Directors declared a quarterly cash dividend of $0.225 per common share (equivalent to $0.90 per annum) for the third quarter of 2015.
- The dividend is payable on October 15, 2015 to stockholders of record on October 5, 2015, representing an ex-dividend date of October 1, 2015.
Brixmor Property Group Inc. owns and operates various grocery-anchored community and neighborhood shopping centers in the United States. As of March 31, 2013, the company owned interests in 532 community and neighborhood shopping centers comprising 526 wholly owned community and neighborhood shopping centers; and 6 community and neighborhood shopping centers held through unmerged real estate joint ventures. Brixmor Property Group Inc. was formerly known as CENTRO SUPER RESIDUAL HOLDING 2 LLC.
Amkor Technology, Inc. (NASDAQ:AMKR), during its Tuesday’s current trading session decreased -14.84% to $4.20.
Amkor Technology, Inc. (AMKR), a leading provider of semiconductor packaging and test services, declared financial results for the second quarter ended June 30, 2015.
Second quarter 2015 results comprise a $9 million ($0.04 per diluted share) charge for the early extinguishment of debt related to the redemption of all $345 million aggregate principal amount of Amkor’s outstanding 7.375% Senior Notes due 2018. Second quarter 2014 results comprise a net gain of $18 million ($0.08 per diluted share) related to the sale of Amkor’s Japanese partner to J-Devices, its joint venture in Japan.
During the second quarter we accomplished the redemption of our 7.375% Senior Notes due 2018 using cash on hand and borrowings under our credit facilities which bear interest at floating rates tied to LIBOR. Based on current interest rates, we expect to save about $17 million in annual interest expense from the redemption.
Amkor Technology, Inc. provides outsourced semiconductor packaging and test services in the United States, China, Ireland, Japan, Singapore, Taiwan, Thailand, and internationally. The company offers turnkey packaging and test services, counting semiconductor wafer bumps, wafer probes, wafer backgrinds, package design, packaging, and test and drop shipment services. Its packages employ wirebond, flip chip, and copper clip interconnect technologies; and leadframe and substrate package carriers are used for various testing services.
Finally, CTI BioPharma Corp (NASDAQ:CTIC), gained 1.34%, to $1.88.
CTI BioPharma Corp. (CTIC) declared that it plans to report its second quarter 2015 financial results on Thursday, August 6, 2015, after the close of the U.S. financial markets. Following the declarement, members of the administration team will host a webcast conference call to talk about the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m. PDT).
CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an oral multikinase inhibitor with activity against Janus Kinase 2 and FMS-like tyrosine kinase, which is in Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II/III clinical trials for the treatment of acute myeloid leukemia; and Opaxio, a chemotherapeutic agent, which is in Phase III clinical trials for the treatment of various solid tumors, counting non-small cell lung, ovarian, breast, and prostate cancers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
